These data support the use of a PI3K inhibitor as a concurrent treatment to pharmacologically downregulate Cyclin D1 prior to platinum therapy, a combinatory strategy whose feasibility has already been demonstrated in Phase I studies in HNSCC patients36. This evidence concerns the gene CCND1 and head and neck squamous cell carcinoma.